Antigen receptors and uses thereof
AssigneesBioNTech Cell & Gene Therapies GmbH, Tron - Translationale Onkologie An Der UniversitäTsmedizin Der Johannes Gutenb
InventorsRalf Holger VOSS, Ugur SAHIN, Matthias THEOBALD, Petra SIMON, Matthias BIRTEL
Life of this patent
Estimating the term…
Abstract
The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
Claims21
A membrane bound antigen receptor, which receptor comprises a first peptide chain and a second peptide chain, wherein
- the first peptide chain comprises at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR alpha chain constant domain (Cα), and
- the second peptide chain comprises at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR beta chain constant domain (Cβ);
- or
- the first peptide chain comprises at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR alpha chain constant domain (Cα), and
- the second peptide chain comprises at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR beta chain constant domain (Cβ);
- or
- the first peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR alpha chain constant domain (Cα), and
- the second peptide chain comprises at least two immunoglobulin heavy chain variable domains (VH) and a human TCR beta chain constant domain (Cβ);
- or
- the first peptide chain comprises at least two immunoglobulin heavy chain variable domains (VH) and a human TCR alpha chain constant domain (Cα);
- and
- the second peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR beta chain constant domain (Cβ);
- and
- wherein a first VH or VL domain from the first peptide chain forms a first antigen binding site together with a first VL or VH domain, respectively, from the second peptide chain, and
- wherein a second VH or VL domain from the first peptide chain forms a second antigen binding site together with a second VL or VH domain, respectively, from the second peptide chain, and
- wherein the antigen receptor does not comprise a variable region of a T cell receptor chain.
A peptide chain comprising
- an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR alpha chain constant domain (Cα);
- or
- an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR beta chain constant domain (Cβ);
- or
- an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR alpha chain constant domain (Cα), or an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR beta chain constant domain (Cβ);
- or
- at least two immunoglobulin light chain variable domains (VL) and a human TCR alpha chain constant domain (Cα), or
- at least two immunoglobulin heavy chain variable domains (VH) and a human TCR beta chain constant domain (Cβ);
- or
- at least two immunoglobulin heavy chain variable domains (VH) and a human TCR alpha chain constant domain (Cα);
- or
- at least two immunoglobulin light chain variable domains (VL) and a human TCR beta chain constant domain (Cβ);
- or
- an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL), a human TCR alpha chain constant domain (Cα), and a transmembrane domain;
- or
- an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH), a human TCR beta chain constant domain (Cβ), and a transmembrane domain;
- or
- an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH), a human TCR alpha chain constant domain (Cα), and a transmembrane domain, or
- an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL), a human TCR beta chain constant domain (Cβ), and a transmembrane domain;
- or
- at least two immunoglobulin light chain variable domains (VL), a human TCR alpha chain constant domain (Cα), and a transmembrane domain, or
- at least two immunoglobulin heavy chain variable domains (VH), a human TCR beta chain constant domain (Cβ), and a transmembrane domain;
- or
- at least two immunoglobulin heavy chain variable domains (VH), a human TCR alpha chain constant domain (Cα), and a transmembrane domain;
- or
- at least two immunoglobulin light chain variable domains (VL), a human TCR beta chain constant domain (Cβ), and a transmembrane domain,
- wherein the peptide chain does not comprise a variable region of a T cell receptor chain.
An ex vivo method for producing a cell expressing a membrane bound antigen receptor which receptor comprises a first peptide chain and a second peptide chain, the method comprising:
- (a) providing a human cell;
- (b) providing a first genetic construct encoding the first peptide chain comprising:
- (i) at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR alpha chain constant domain (Cα);
- or
- (ii) at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR alpha chain constant domain (Cα);
- or
- (iii) at least two immunoglobulin light chain variable domains (VL) and a human TCR alpha chain constant domain (Cα), or
- (iv) at least two immunoglobulin heavy chain variable domains (VH) and a human TCR alpha chain constant domain (Cα);
- and
- (c) providing a second genetic construct encoding the second peptide chain comprising:
- (i) at least of an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR beta chain constant domain (Cβ);
- or
- (ii) comprising at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR beta chain constant domain (Cβ);
- or
- (iii) at least two immunoglobulin heavy chain variable domains (VH) and a human TCR beta chain constant domain (Cβ);
- or
- (iv) at least two immunoglobulin light chain variable domains (VL) and a human TCR beta chain constant domain (Cβ);
- (d) introducing first genetic construct (i) and second genetic construct (ii) into the cell, or first genetic construct (ii) and second genetic construct (i) into the cell, or first and second genetic constructs (iii) into the cell, or first and second genetic constructs (iv) into the cell;
- and
- (e) allowing the constructs to be expressed in the cell;
- wherein the cell is a T cell,
- wherein either the first genetic construct or the second genetic construct further comprises a transmembrane domain,
- wherein neither the first genetic construct nor the second genetic construct comprises a variable region of a T cell receptor chain,
- wherein a first VH or VL domain from the first peptide chain is able to form a first antigen binding site together with a first VL or VH domain, respectively, from the second peptide chain,
- wherein a second VH or VL domain from the first peptide chain is able to form a second antigen binding site together with a second VL or VH domain, respectively, from the second peptide chain, and
- wherein the first peptide chain and the second peptide chain are provided on a single genetic construct or two separate constructs.
Dependencies are inferred from the claim text.